全文获取类型
收费全文 | 6697篇 |
免费 | 408篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 228篇 |
妇产科学 | 202篇 |
基础医学 | 826篇 |
口腔科学 | 165篇 |
临床医学 | 508篇 |
内科学 | 1770篇 |
皮肤病学 | 117篇 |
神经病学 | 581篇 |
特种医学 | 157篇 |
外科学 | 1074篇 |
综合类 | 34篇 |
一般理论 | 1篇 |
预防医学 | 404篇 |
眼科学 | 91篇 |
药学 | 282篇 |
中国医学 | 18篇 |
肿瘤学 | 605篇 |
出版年
2023年 | 61篇 |
2022年 | 123篇 |
2021年 | 319篇 |
2020年 | 142篇 |
2019年 | 246篇 |
2018年 | 269篇 |
2017年 | 190篇 |
2016年 | 169篇 |
2015年 | 172篇 |
2014年 | 261篇 |
2013年 | 340篇 |
2012年 | 536篇 |
2011年 | 593篇 |
2010年 | 307篇 |
2009年 | 273篇 |
2008年 | 411篇 |
2007年 | 429篇 |
2006年 | 414篇 |
2005年 | 389篇 |
2004年 | 304篇 |
2003年 | 274篇 |
2002年 | 241篇 |
2001年 | 75篇 |
2000年 | 59篇 |
1999年 | 72篇 |
1998年 | 48篇 |
1997年 | 36篇 |
1996年 | 22篇 |
1995年 | 24篇 |
1994年 | 21篇 |
1993年 | 21篇 |
1992年 | 32篇 |
1991年 | 24篇 |
1990年 | 20篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 20篇 |
1985年 | 5篇 |
1984年 | 11篇 |
1983年 | 13篇 |
1981年 | 13篇 |
1980年 | 7篇 |
1979年 | 13篇 |
1978年 | 7篇 |
1977年 | 12篇 |
1976年 | 20篇 |
1975年 | 6篇 |
1974年 | 7篇 |
1969年 | 4篇 |
排序方式: 共有7139条查询结果,搜索用时 15 毫秒
81.
Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention 总被引:2,自引:0,他引:2
Juan F. Ascaso Arturo Fernández-Cruz Pedro González Santos Antonio Hernández Mijares Alipio Mangas Rojas Prof. Jesus Millán Luis Felipe Pallardo Juan Pedro-Botet Francisco Pérez-Jiménez Gonzalo Pía Xavier Pintó Ignacio Plaza Juan Rubiés-Prat 《Am J Cardiovasc Drugs》2004,4(5):299-314
In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (<100 mg/dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (>20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome. 相似文献
82.
83.
Ahmad Agil Russel J. Reiter Aroa Jiménez‐Aranda Ruth Ibán‐Arias Miguel Navarro‐Alarcón Juan Antonio Marchal Abdu Adem Gumersindo Fernández‐Vázquez 《Journal of pineal research》2013,54(4):381-388
The aim of this study was to investigate the effects of melatonin on low‐grade inflammation and oxidative stress in young male Zucker diabetic fatty (ZDF) rats, an experimental model of metabolic syndrome and type 2 diabetes mellitus (T2DM). ZDF rats (n = 30) and lean littermates (ZL) (n = 30) were used. At 6 wk of age, both lean and fatty animals were subdivided into three groups, each composed of 10 rats: naive (N), vehicle treated (V), and melatonin treated (M) (10 mg/kg/day) for 6 wk. Vehicle and melatonin were added to the drinking water. Pro‐inflammatory state was evaluated by plasma levels of interleukin‐6 (IL‐6), tumor necrosis factor‐α (TNF‐α), and C‐reactive protein (CRP). Also, oxidative stress was assessed by plasma lipid peroxidation (LPO), both basal and after Fe2+/H2O2 inducement. ZDF rats exhibited higher levels of IL‐6 (112.4 ± 1.5 pg/mL), TNF‐α (11.0 ± 0.1 pg/mL) and CRP (828 ± 16.0 µg/mL) compared with lean rats (IL‐6, 89.9 ± 1.0, P < 0.01; TNF‐α, 9.7 ± 0.4, P < 0.01; CRP, 508 ± 21.5, P < 0.001). Melatonin lowered IL‐6 (10%, P < 0.05), TNF‐α (10%, P < 0.05), and CRP (21%, P < 0.01). Basal and Fe2+/H2O2‐induced LPO, expressed as malondialdehyde equivalents (µmol/L), were higher in ZDF rats (basal, 3.2 ± 0.1 versus 2.5 ± 0.1 in ZL, P < 0.01; Fe2+/H2O2‐induced, 8.7 ± 0.2 versus 5.5 ± 0.3 in ZL; P < 0.001). Melatonin improved basal LPO (15%, P < 0.05) in ZDF rats, and Fe2+/H2O2‐ induced LPO in both ZL (15.2%, P < 0.01) and ZDF rats (39%, P < 0.001). These results demonstrated that oral melatonin administration ameliorates the pro‐inflammatory state and oxidative stress, which underlie the development of insulin resistance and their consequences, metabolic syndrome, diabetes, and cardiovascular disease. 相似文献
84.
Jose R. Gonzalez‐Porras Fernando Escalante Emilia Pardal Magdalena Sierra Luis J. Garcia‐Frade Santiago Redondo Maryam Arefi Carlos Aguilar Fernando Ortega Erik de Cabo Rosa M. Fisac Oscar Sanz Carmen Esteban Ignacio Alberca Mercedes Sanchez‐Barba Maria T. Santos Abel Fernandez Tomas J. Gonzalez‐Lopez representing the Grupo de Trombosis y Hemostasia de Castilla y León 《European journal of haematology》2013,91(3):236-241
85.
86.
Hernando V Sobrino-Vegas P Burriel MC Berenguer J Navarro G Santos I Reparaz J Martínez MA Antela A Gutiérrez F Del Amo J;for CoRIS cohort 《AIDS (London, England)》2012,26(14):1829-1834
OBJECTIVES:: To compare causes of death (CoDs) from two independent sources: National Basic Death File (NBDF) and deaths reported to the Spanish HIV Research cohort [Cohort de adultos con infección por VIH de la Red de Investigación en SIDA CoRIS)] and compare the two coding algorithms: International Classification of Diseases, 10th revision (ICD-10) and revised version of Coding Causes of Death in HIV (revised CoDe). METHODS:: Between 2004 and 2008, CoDs were obtained from the cohort records (free text, multiple causes) and also from NBDF (ICD-10). CoDs from CoRIS were coded according to ICD-10 and revised CoDe by a panel. Deaths were compared by 13 disease groups: HIV/AIDS, liver diseases, malignancies, infections, cardiovascular, blood disorders, pulmonary, central nervous system, drug use, external, suicide, other causes and ill defined. RESULTS:: There were 160 deaths. Concordance for the 13 groups was observed in 111 (69%) cases for the two sources and in 115 (72%) cases for the two coding algorithms. According to revised CoDe, the commonest CoDs were HIV/AIDS (53%), non-AIDS malignancies (11%) and liver related (9%), these percentages were similar, 57, 10 and 8%, respectively, for NBDF (coded as ICD-10). When using ICD-10 to code deaths in CoRIS, wherein HIV infection was known in everyone, the proportion of non-AIDS malignancies was 13%, liver-related accounted for 3%, while HIV/AIDS reached 70% due to liver-related, infections and ill-defined causes being coded as HIV/AIDS. CONCLUSION:: There is substantial variation in CoDs in HIV-infected persons according to sources and algorithms. ICD-10 in patients known to be HIV-positive overestimates HIV/AIDS-related deaths at the expense of underestimating liver-related diseases, infections and ill defined causes. CoDe seems as the best option for cohort studies. 相似文献
87.
88.
Ignacio Mejía‐Calvo Leonardo E. Lpez‐Jurez Said Vzquez‐Leyva Carlos A. Lpez‐Morales Daniel Montoya‐Escutia Pamela G. Merlos Rivera Jos Enrique Herbert‐Pucheta Luis Gerardo Zepeda‐Vallejo Marco Velasco‐Velzquez Lenin Pavn Sonia M. Prez‐Tapia Emilio Medina‐Rivero 《Journal of Cosmetic Dermatology》2021,20(1):150-158
89.
90.